LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01257477 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2013-04-04
Summary
An observational study to evaluate LOTRONEX® in women with severe IBS-D in the current clinical practice setting.
Conditions
- Irritable Bowel Syndrome
Sponsors & Collaborators
-
Prometheus Laboratories
lead INDUSTRY
Principal Investigators
-
Emil Chuang, MD · Prometheus Therapeutics and Diagnostics
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2013-03-31
- Completion
- 2013-03-31
Countries
- United States
Study Locations
More Related Trials
-
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
NCT04043455 ·Status: TERMINATED ·Phase: PHASE2
-
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03573908 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Dietary Supplementation on Intestinal Barrier Function in IBS-D
NCT06543498 ·Status: COMPLETED ·Phase: NA
-
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
NCT01494233 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT03977155 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
NCT00215566 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT00394173 ·Status: COMPLETED ·Phase: PHASE2
-
Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D)
NCT00745004 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
NCT01553591 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
NCT01553747 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide
NCT00584298 ·Status: COMPLETED ·Phase: PHASE1
-
8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
NCT00230581 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
NCT01358708 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
NCT00547469 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
NCT05134584 ·Status: UNKNOWN ·Phase: PHASE4
-
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01923428 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01844180 ·Status: COMPLETED ·Phase: PHASE2
-
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT02107196 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT04129619 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT00460811 ·Status: COMPLETED ·Phase: PHASE2
-
Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
NCT01303224 ·Status: COMPLETED ·Phase: PHASE2
-
Microbiota Profiling in IBS
NCT03720314 ·Status: COMPLETED
-
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
NCT06676514 ·Status: COMPLETED ·Phase: NA
-
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT02120027 ·Status: TERMINATED ·Phase: PHASE3
-
Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)
NCT00610909 ·Status: COMPLETED ·Phase: PHASE4